Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 1, p. 20, doi. 10.1177/1756285614564152
- By:
- Publication type:
- Article
Works matching IS 17562856 AND DT 2015 AND VI 8 AND IP 1
Results: 5
1
2
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 1, p. 31, doi. 10.1177/1756285614563522
- By:
- Publication type:
- Article
3
Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 1, p. 14, doi. 10.1177/1756285614563056
- By:
- Publication type:
- Article
4
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 1, p. 46, doi. 10.1177/1756285614562419
- By:
- Publication type:
- Article
5
Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 1, p. 3, doi. 10.1177/1756285614560733
- By:
- Publication type:
- Article